Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Roche’s Tecentriq triplet versus Keytruda + chemotherapy: an Uphill Struggle?

Although Roche’s triplet therapy faces many challenges in making headway against Merck’s combination, the setting of first-line NSCLC remains one of the most profitable markets for immuno-oncology drugs. Credit: Courtesy of Oregon State University



  • Roche’s triple therapy

Go Top